Phaseline

Companies › Aulos Bioscience

Aulos Bioscience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AU-007 (imneskibart)
Monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding
IL2Phase 1Advanced Solid TumorFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05267626AU-007 (imneskibart)Phase 1Advanced Solid TumorOncologyFeb 2027

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics Synthekine Nektar Therapeutics HCW Biologics Asher Biotherapeutics Regeneron Pharmaceuticals Salspera

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.